QR-313

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameQR-313
Drug Alias NameQR-313
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionCollagen alpha-1(VII) chain modulators
TargetsCollagen alpha-1(VII) chain
Therapy Area/IndicationsEpidermolysis Bullosa Dystrophica
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFranceSpain
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesProqr Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPhoenicis Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsEpidermolysis Bullosa Dystrophica

Other Information

ATC CodeN/A
Related LinksN/A